Early IGF-1 Gene Therapy Prevented Oxidative Stress and Cognitive Deficits Induced by Traumatic Brain Injury

MONTIVERO, AGUSTÍN. J.; GHERSI, MARISA. S.; SILVERO C, M. JAZMÍN; ARTUR DE LA VILLARMOIS, EMILCE; CATALAN-FIGUEROA, JOHANNA; HERRERA, MACARENA; BECERRA, MARÍA CECILIA; HEREÑÚ, CLAUDIA. B.; PÉREZ, MARIELA. F.

Frontiers in Pharmacology

Frontiers Media S.A.

Lugar: Lausanne; Año: 2021 vol. 12

raumatic Brain Injury (TBI) remains a leading cause of morbidity and mortality in adults under 40 years old. Once primary injury occurs after TBI, neuroinflammation and oxidative stress (OS) are triggered, contributing to the development of many TBI-induced neurological deficits, and reducing the probability of critical trauma patients´ survival. Regardless the research investment on the development of anti-inflammatory and neuroprotective treatments, most pre-clinical studies have failed to report significant effects, probably because of the limited blood brain barrier permeability of no-steroidal or steroidal anti-inflammatory drugs. Lately, neurotrophic factors, such as the insulin-like growth factor 1 (IGF-1), are considered attractive therapeutic alternatives for diverse neurological pathologies, as they are neuromodulators linked to neuroprotection and anti-inflammatory effects. Considering this background, the aim of the present investigation is to test early IGF-1 gene therapy